Danish pharmaceutical giant Novo Nordisk took revenge on the Copenhagen Stock Exchange after Monday's price drop.
The stock bounced back and was up 4.5 percent by the close. Just like Monday's 5.8 percent drop, the results of a newly published study are causing the stock to react strongly.
The company has announced positive results from a phase 2 study of the drug candidate Amycretin in people with type 2 diabetes. The results show a significant weight loss of up to 14.5 percent after 36 weeks, the company writes.
However, today's rise should be put into perspective that the share price has still fallen 53 percent since the turn of the year.
